IRIS

Reply to Costs of ALK, ROS1, EGFR, and KRAS Testing in Non-Small Cell Lung Cancer: About Different Strategies in France

Reply to Costs of ALK, ROS1, EGFR, and KRAS testing in nonâ small cell lung cancer: About different strategies in France / Troncone, Giancarlo. - In: CANCER CYTOPATHOLOGY. - ISSN 1934-662X. - 125:11(2017), pp. 877-877. [10.1002/cncy.21918]

Reply to Costs of ALK, ROS1, EGFR, and KRAS testing in non–small cell lung cancer: About different strategies in France

Troncone, Giancarlo
2017

Abstract

Reply to Costs of ALK, ROS1, EGFR, and KRAS Testing in Non-Small Cell Lung Cancer: About Different Strategies in France
2017
Reply to Costs of ALK, ROS1, EGFR, and KRAS testing in nonâ small cell lung cancer: About different strategies in France / Troncone, Giancarlo. - In: CANCER CYTOPATHOLOGY. - ISSN 1934-662X. - 125:11(2017), pp. 877-877. [10.1002/cncy.21918]
1.7 Commento, erratum, replica e simili
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/712604
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact